-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BDrLq8/tbuEMm1lFWTJsqZAP+tIPX6BcI8cUVDdBUOMlG/Wf7nmLfz2O0Pe4kkAm b55EGXlDOm59z7h7QUKT4g== 0001144204-10-038397.txt : 20100719 0001144204-10-038397.hdr.sgml : 20100719 20100719161144 ACCESSION NUMBER: 0001144204-10-038397 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100715 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20100719 DATE AS OF CHANGE: 20100719 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOANALYTICAL SYSTEMS INC CENTRAL INDEX KEY: 0000720154 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 351345024 STATE OF INCORPORATION: IN FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23357 FILM NUMBER: 10958547 BUSINESS ADDRESS: STREET 1: 2701 KENT AVE CITY: WEST LAFAYETT STATE: IN ZIP: 47906-1382 BUSINESS PHONE: 3174634527 MAIL ADDRESS: STREET 1: 2701 KENT AVENUE CITY: WEST LAFAYETTE STATE: IN ZIP: 47906-1382 8-K 1 v190911_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): July 15, 2010
 
BIOANALYTICAL SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

Indiana
  
0-23357
  
35-1345024
(State or other
jurisdiction of
incorporation or
organization)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)
 
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
  
 
47906-1382
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))
 
 
 
 

Item 3.01.   Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 15, 2010, Bioanalytical Systems, Inc. (the "Company") received a letter from the NASDAQ Listing Qualification Department (the "Letter") stating that the Company has failed to maintain at least a $1.00 minimum bid price for its common shares (the "Minimum Bid Requirement") as required for continued listing of the Company's common shares on the NASDAQ Capital Market..

The Letter further stated that, under the listing rules, the Company has until January 11, 2011 to regain compliance with the Minimum Bid Requirement.  If, at any time prior to January 11, 2011, the bid price of the common shares closes at $1.00 or more for a minimum of 10 consecutive business days, the Company will be in compliance with the Minimum Bid Requirement.  The Company intends to actively evaluate and monitor the bid price for its common shares between now and January 11, 2011, and consider implementation of various options available to the Company if its common shares do not trade at a level that is likely to regain compliance.  If the Company's minimum bid does not increase to $1.00 per share or more for 10 consecutive business days prior to January 11, 2011, the Company could be delisted from the NASDAQ Capital Market, in which case the common shares may be traded over-the-counter.

 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Bioanalytical Systems, Inc.
     
Date:  July 19, 2010
By:
/s/ Michael R. Cox
   
Michael R. Cox
   
Vice President, Finance and Administration, Chief
Financial Officer and Treasurer
 
 
 
 

-----END PRIVACY-ENHANCED MESSAGE-----